Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $...
Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 mill...
Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08)...
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Stev...
